Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tizanidine versus melatonin for tourniquet pain tolerance during intravenous regional anesthesia
IRCT20260801070479N1Phase 3Recruiting
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tizanidine, melatonin and lidocaine (3 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoints: Tourniquet pain tolerance, Time of onset of tourniquet pain and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
tizanidinemelatoninlidocaine
Beyond the preview
Go deeper on IRCT20260801070479N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260801070479N1.